Clinical trial · no report yet · Phase 3
IMforte
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
- NCT05091567 ↗
- Active not recruiting
- Hoffmann-La Roche
- 187 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 127 | |
| YouTube | 34 | |
| Podcasts | 24 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomized, Open-Label, Multicenter Study of Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab as Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following First-Line Induction Therapy With Carboplatin, Etoposide and Atezolizumab
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Small-Cell Lung Cancer
- Interventions
- Atezolizumab; Lurbinectedin; Carboplatin; Etoposide
- Arms
- Arm A: Atezolizumab+Lurbinectedin · Experimental
- Arm B: Atezolizumab · Active comparator
- Enrollment
- 660
- Primary outcomes
- Randomized Phase: Independent Review Facility (IRF) - Assessed Progression Free Survival (PFS)
- Randomized Phase: Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche with Jazz Pharmaceuticals
- Start
- Nov 18, 2021
- Primary completion
- Jul 29, 2024
- Results posted
- Yes
- Registry record
- NCT05091567 · updated Sep 9, 2026
Publications
linked from the registry- Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K, Majem M, Sendur MAN, Czyzewicz G, Caro RB, Lee KH, Johnson ML, Karadurmus N, Grohe C, Baka S, Csoszi T, Ahn JS, Califano R, Yang TY, Kemal Y, Ballinger M, Cuchelkar V, Graupner V, Lin YC, Chakrabarti D, Bhatt K, Cai G, Iannone R, Reck M; IMforte investigators. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 14;405(10495):2129-2143. doi: 10.1016/S0140-6736(25)01011-6. Epub 2025 Jun 2. PubMed 40473449